• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Akoya BioSciences Inc.

    3/17/25 4:15:51 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AKYA alert in real time by email
    S-8 1 tm259213d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 17, 2025

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

     

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

     

    Akoya Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-5586242

    (State or other jurisdiction

    of incorporation or organization)

     

     

    (I.R.S. Employer

    Identification No.)

    100 Campus Drive, 6th Floor

    Marlborough, MA

      01752
    (Address of principal executive offices)   (Zip code)

     

    Akoya Biosciences, Inc. 2021 Equity Incentive Plan

    Akoya Biosciences, Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plan)

     

    Brian McKelligon

    Chief Executive Officer

    Akoya Biosciences, Inc.

    100 Campus Drive, 6th Floor

    Marlborough, MA 01752

    (855) 896-8401

    (Name, address and telephone number, including area code, of agent for service)

     

    Copy to:

     

    Patrick O’Malley, Esq.

    DLA Piper LLP (US)

    4365 Executive Drive, Suite 1100

    San Diego, CA 92121

    Tel: (858) 677-1400

    Fax: (858) 677-1401

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer   ¨   Accelerated filer   ¨
    Non-accelerated filer   x   Smaller reporting company   x
            Emerging growth company   x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ¨

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

     

    Pursuant to General Instruction E to Form S-8, this Registration Statement is being filed for the purpose of registering an additional (i) 2,478,606 shares of the Registrant’s common stock to be issued pursuant to the Registrant’s 2021 Equity Incentive Plan; and (ii) 247,860 shares of the Registrant’s common stock to be issued pursuant to the Registrant’s 2021 Employee Stock Purchase Plan, which are the same class as those securities previously registered on effective Form S-8 filed with the Securities and Exchange Commission on April 23, 2021 (File No. 333-255468) (the “Original Registration Statement”), March 15, 2022 (File No. 333-263548), March 7, 2023 (File No. 333-270312) and March 5, 2024 (File No. 333-277648). The contents of the Original Registration Statement, as amended, or as modified or superseded pursuant to Rule 412 under the Securities Act, are incorporated by reference into this Registration Statement.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit No.

    Description
       
    4.1(1) Amended and Restated Certificate of Incorporation of the Registrant.
       
    4.2(2) Amended and Restated Bylaws of the Registrant.
       
    4.3(3) Description of Capital Stock
       
    5.1 Opinion of DLA Piper LLP (US).
       
    23.1 Consent of RSM US LLP, an independent registered public accounting firm.
       
    23.2 Consent of DLA Piper LLP (US) (filed as a part of Exhibit 5.1).
       
    24.1 Power of Attorney (contained on signature page).
       
    99.1(4)# 2021 Equity Incentive Plan.
       
    99.2(5)# 2021 Employee Stock Purchase Plan.
       
    99.3# Form of Stock Option Grant Notice and Stock Option Agreement for 2021 Equity Incentive Plan
       
    99.4# Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for 2021 Equity Incentive Plan
       
    107 Filing Fee Exhibit.

     

    (1)Previously filed as Exhibit 3.3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-254760), originally filed with the Commission on March 26, 2021, as amended, and incorporated herein by reference.

     

    (2)Previously filed as Exhibit 3.1 to the Registrant’s Form 8-K (File No. 001-40344), filed with the Commission on September 6, 2023, and incorporated herein by reference.

     

    (3)Previously filed as exhibit 4.2 to the Registrant’s Annual Report on Form 10-K (File No. 001-40344), filed with the Commission on March 7, 2023, and incorporated herein by reference.

     

    (4)Previously filed as Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-254760), filed with the Commission on April 12, 2021, and incorporated herein by reference.

     

    (5)Previously filed as Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-254760), filed with the Commission on April 12, 2021, and incorporated herein by reference.

     

    #Indicates a management contract or compensatory plan or arrangement.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned thereunto duly authorized in the City of Marlborough, State of Massachusetts, on March 17, 2025.

     

      AKOYA BIOSCIENCES, INC.
         
      By: /s/ Brian McKelligon
        Brian McKelligon
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose individual signature appears below hereby authorizes and appoints Brian McKelligon and Johnny Ek, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name    Title    Date 
             
    /s/ Brian McKelligon   President, Chief Executive Officer and Director    March 17, 2025
    Brian McKelligon       (Principal Executive Officer)          
             
    /s/ Johnny Ek   Chief Financial Officer   March 17, 2025
    Johnny Ek                
             
    /s/ Scott Mendel   Chair of the Board   March 17, 2025
    Scott Mendel            
             
    /s/ Thomas Raffin, MD   Director    March 17, 2025
    Thomas Raffin, MD                  
             
    /s/ Thomas P. Schnettler   Director    March 17, 2025
    Thomas P. Schnettler                  
             
    /s/ Robert Shepler   Director   March 17, 2025
    Robert Shepler        
             
    /s/ Matthew Winkler, PhD   Director   March 17, 2025
    Matthew Winkler, PhD            
             
    /s/ Myla Lai-Goldman, MD   Director   March 17, 2025
    Myla Lai-Goldman, MD                  

     

     

     

    Get the next $AKYA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKYA

    DatePrice TargetRatingAnalyst
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    8/6/2024Overweight → Equal-Weight
    Morgan Stanley
    8/6/2024Buy → Neutral
    BTIG Research
    8/6/2024Overweight → Neutral
    JP Morgan
    6/21/2024$7.50Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    7/5/2023$18.00Overweight
    JP Morgan
    2/2/2023$14.00Buy
    UBS
    More analyst ratings

    $AKYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Akoya Biosciences downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously

    11/15/24 8:33:16 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences downgraded by Morgan Stanley

    Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight

    8/6/24 12:17:30 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences downgraded by BTIG Research

    BTIG Research downgraded Akoya Biosciences from Buy to Neutral

    8/6/24 6:28:51 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

    RINCON, Puerto Rico, May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ:AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya. On May 20, 20

    5/23/25 2:21:00 PM ET
    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences Reports First Quarter 2025 Financial Results

    MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

    5/12/25 4:05:00 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

    It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") relat

    4/30/25 8:00:00 AM ET
    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mendel Scott disposed of 28,500 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

    7/10/25 8:41:09 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Business Officer Ramachandran Niro Ph.D acquired 62,566 shares, covered exercise/tax liability with 42,148 shares and disposed of 282,555 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

    7/10/25 8:40:45 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Mckelligon Brian disposed of 947,688 shares, acquired 724,428 shares and covered exercise/tax liability with 196,866 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

    7/10/25 8:40:22 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    SEC Filings

    View All

    SEC Form 15-12G filed by Akoya BioSciences Inc.

    15-12G - Akoya Biosciences, Inc. (0001711933) (Filer)

    7/18/25 9:25:03 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form EFFECT filed by Akoya BioSciences Inc.

    EFFECT - Akoya Biosciences, Inc. (0001711933) (Filer)

    7/14/25 12:15:03 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form S-8 POS filed by Akoya BioSciences Inc.

    S-8 POS - Akoya Biosciences, Inc. (0001711933) (Filer)

    7/8/25 1:06:41 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    Leadership Updates

    Live Leadership Updates

    View All

    Akoya Biosciences Announces Leadership Transition

    Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ

    3/20/23 4:00:00 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

    MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen

    2/28/23 8:00:00 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

    MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the

    4/19/22 8:05:00 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    Financials

    Live finance-specific insights

    View All

    Akoya Biosciences Reports First Quarter 2025 Financial Results

    MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

    5/12/25 4:05:00 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

    MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

    3/17/25 4:00:00 PM ET
    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

    Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ

    1/10/25 7:00:00 AM ET
    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Akoya BioSciences Inc.

    SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

    11/4/24 7:39:24 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Akoya BioSciences Inc.

    SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)

    8/28/24 10:45:17 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Akoya BioSciences Inc. (Amendment)

    SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

    2/14/24 4:09:03 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials